reports
Medicenna Therapeutics Corp: 1 director
A director at Medicenna Therapeutics Corp bought 20,000 shares at 1.450CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink ...
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse model of triple negative breast cancer (TNBC) Mice treated with MDNA11 prior to surgery were able to mount powerful immune and memory response to subsequent tumor rechallenges, demonstrating potential to prevent new tumor grow...
Medicenna Provides Clinical Update and Announces First Complete Respon...
Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) Complete regression of all tumors in two CPI-resistant patients in monotherapy arms continue to show durability with a patient with melanoma remaining tumor free at week 63 whil...
Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongo...
Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that updated clinical data from the ongoing Phase 1/2 ABILITY-1 study will be presented as part of an oral podium presentation at the 2024 Immunotherapy Bridge Conference, taking place from Decemb...
Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 20...
Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing anti-tumor immunity Combination therapy with MDNA11 and Bizaxofusp demonstrates synergistic tumor-killing in human GBM tumoroids TORONTO and HOUSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQ...
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Cor...
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more immune checkpoint inhibitor (ICI) therapy Two PRs were observed among 3 microsatellite instability high (MSI-H) ICI resistant patients (ORR 66.7%) with both responders having pancreatic cancer including one patient with 100% tumor regression and no progression of target and non-target lesions for...
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting ...
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present pre-clinical data on MDNA11 and IL-2 Superkines in glioblastoma models at the 29th Annual Meeting of the Society of Neuro-Oncology (SNO) taking place in Houston, Texas ...
Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose...
Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with immune checkpoint inhibitor (ICI) therapy Among ICI-resistant, high-dose MDNA11, phase 2-eligible patients in the monotherapy escalation and expansion cohorts (N=20), the response rate is 25% (5/2...
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and ...
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases MDNA113 treatment achieved complete tumor regression of IL-13Rα2 expressing tumors, highlighting its potential to treat a vast range of malig...
Medicenna to Present Clinical and Preclinical Data at the 39th Annual ...
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked, tumor-targeted bifunctional anti-PD1-IL-2 Superkine, and on its IL-2 agonists in glioblastoma, will also be presented TORONTO and HOUSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a ...
Medicenna Announces Results of Annual Meeting of Shareholders
Medicenna Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results from the Company’s annual meeting of shareholders held today, September 26, 2024 (the “Meeting”). Medicenna is pleased to announce that all nominees listed in the management information circular dated August 14, 2024 (the “Circular”), were elected as directors. The results of th...
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist ...
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and affecting 5 to 10% of the global population MDNA209 restores immune balance by selectively blocking IL-2Rβγc, a receptor highly expressed by effector CD8 T cells which are known to promote tissue damage in autoimmune diseases In an aggressive...
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Inv...
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. Details on the fireside chat are...
Medicenna Announces Upcoming Presentations at The Promise of Interleuk...
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that the Company will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. The Company will...
Medicenna Strengthens Board of Directors with Appointment of Karim Lal...
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today the appointment of Mr. Karim Lalji as a new addition to its Board of Directors effective as of August 14, 2024. “We are thrilled to announce the appointment of Mr. Karim Lalji as a new member to our Board of Directors,” said Dr. Fahar Merchant, President and CEO of Medicenna. “With...
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Anno...
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response following treatment with MDNA11 at week 52 with 100% regression of all target and non-target lesions reinforcing its best-in-class potential Updated scans from pancreatic cancer patient continues to show sustained 100% regression of target and non-target lesions at 115 weeks and remains in remission 6 months after ending MDNA11 treatment All other previousl...
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and ...
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development Results presented at the Annual Meeting of the AACR showed single agent MDNA11 response rate of 29% (4/14) in patients with checkpoint resistant tumors Combination dose escalation with pembrolizumab (KEYTRUDA) continues ...
Medicenna Announces EMA Approval of its Clinical Trial Application to ...
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe - ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®, at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monotherapy expansion and combination escalation data of the ABILITY-1 study are expected in H2 2024 TORONTO and HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company...
Medicenna Reports Significant Survival Benefit in Patients with Recurr...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL-4 receptor (IL-4R) expression in unresectable recurrent glioblastoma (rGBM) patients in the Phase 2b Study Biz...
Medicenna To Present Evidence of Durable Single Agent Activity and Pot...
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma patient continues to show sustained 100% regression of target lesions Dose escalation in combination with KEYTRUDA® is now enrolling at the next higher dose of 90g/...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.